101 related articles for article (PubMed ID: 38595987)
41. Plasma ceramides are elevated in female children and adolescents with type 2 diabetes.
Lopez X; Goldfine AB; Holland WL; Gordillo R; Scherer PE
J Pediatr Endocrinol Metab; 2013; 26(9-10):995-8. PubMed ID: 23612696
[TBL] [Abstract][Full Text] [Related]
42. Ceramides contained in LDL are elevated in type 2 diabetes and promote inflammation and skeletal muscle insulin resistance.
Boon J; Hoy AJ; Stark R; Brown RD; Meex RC; Henstridge DC; Schenk S; Meikle PJ; Horowitz JF; Kingwell BA; Bruce CR; Watt MJ
Diabetes; 2013 Feb; 62(2):401-10. PubMed ID: 23139352
[TBL] [Abstract][Full Text] [Related]
43. Ceramide synthase 5 mediates lipid-induced autophagy and hypertrophy in cardiomyocytes.
Russo SB; Baicu CF; Van Laer A; Geng T; Kasiganesan H; Zile MR; Cowart LA
J Clin Invest; 2012 Nov; 122(11):3919-30. PubMed ID: 23023704
[TBL] [Abstract][Full Text] [Related]
44. Sphingolipids, lipotoxic cardiomyopathy, and cardiac failure.
Park TS; Goldberg IJ
Heart Fail Clin; 2012 Oct; 8(4):633-41. PubMed ID: 22999245
[TBL] [Abstract][Full Text] [Related]
45. Expression of ceramide-metabolising enzymes in subcutaneous and intra-abdominal human adipose tissue.
Kolak M; Gertow J; Westerbacka J; Summers SA; Liska J; Franco-Cereceda A; Orešič M; Yki-Järvinen H; Eriksson P; Fisher RM
Lipids Health Dis; 2012 Sep; 11():115. PubMed ID: 22974251
[TBL] [Abstract][Full Text] [Related]
46. Spinal muscular atrophy associated with progressive myoclonic epilepsy is caused by mutations in ASAH1.
Zhou J; Tawk M; Tiziano FD; Veillet J; Bayes M; Nolent F; Garcia V; Servidei S; Bertini E; Castro-Giner F; Renda Y; Carpentier S; Andrieu-Abadie N; Gut I; Levade T; Topaloglu H; Melki J
Am J Hum Genet; 2012 Jul; 91(1):5-14. PubMed ID: 22703880
[TBL] [Abstract][Full Text] [Related]
47. Ceramide mediates vascular dysfunction in diet-induced obesity by PP2A-mediated dephosphorylation of the eNOS-Akt complex.
Zhang QJ; Holland WL; Wilson L; Tanner JM; Kearns D; Cahoon JM; Pettey D; Losee J; Duncan B; Gale D; Kowalski CA; Deeter N; Nichols A; Deesing M; Arrant C; Ruan T; Boehme C; McCamey DR; Rou J; Ambal K; Narra KK; Summers SA; Abel ED; Symons JD
Diabetes; 2012 Jul; 61(7):1848-59. PubMed ID: 22586587
[TBL] [Abstract][Full Text] [Related]
48. A ceramide-centric view of insulin resistance.
Chavez JA; Summers SA
Cell Metab; 2012 May; 15(5):585-94. PubMed ID: 22560211
[TBL] [Abstract][Full Text] [Related]
49. Cardiomyocyte specific deficiency of serine palmitoyltransferase subunit 2 reduces ceramide but leads to cardiac dysfunction.
Lee SY; Kim JR; Hu Y; Khan R; Kim SJ; Bharadwaj KG; Davidson MM; Choi CS; Shin KO; Lee YM; Park WJ; Park IS; Jiang XC; Goldberg IJ; Park TS
J Biol Chem; 2012 May; 287(22):18429-39. PubMed ID: 22493506
[TBL] [Abstract][Full Text] [Related]
50. Fenretinide prevents lipid-induced insulin resistance by blocking ceramide biosynthesis.
Bikman BT; Guan Y; Shui G; Siddique MM; Holland WL; Kim JY; Fabriàs G; Wenk MR; Summers SA
J Biol Chem; 2012 May; 287(21):17426-17437. PubMed ID: 22474281
[TBL] [Abstract][Full Text] [Related]
51. Ceramides as modulators of cellular and whole-body metabolism.
Bikman BT; Summers SA
J Clin Invest; 2011 Nov; 121(11):4222-30. PubMed ID: 22045572
[TBL] [Abstract][Full Text] [Related]
52. Sphingolipids and hepatic steatosis.
Bikman BT; Summers SA
Adv Exp Med Biol; 2011; 721():87-97. PubMed ID: 21910084
[TBL] [Abstract][Full Text] [Related]
53. Sphingolipids and cardiovascular diseases: lipoprotein metabolism, atherosclerosis and cardiomyopathy.
Jiang XC; Goldberg IJ; Park TS
Adv Exp Med Biol; 2011; 721():19-39. PubMed ID: 21910080
[TBL] [Abstract][Full Text] [Related]
54. Lipid-induced insulin resistance mediated by the proinflammatory receptor TLR4 requires saturated fatty acid-induced ceramide biosynthesis in mice.
Holland WL; Bikman BT; Wang LP; Yuguang G; Sargent KM; Bulchand S; Knotts TA; Shui G; Clegg DJ; Wenk MR; Pagliassotti MJ; Scherer PE; Summers SA
J Clin Invest; 2011 May; 121(5):1858-70. PubMed ID: 21490391
[TBL] [Abstract][Full Text] [Related]
55. Receptor-mediated activation of ceramidase activity initiates the pleiotropic actions of adiponectin.
Holland WL; Miller RA; Wang ZV; Sun K; Barth BM; Bui HH; Davis KE; Bikman BT; Halberg N; Rutkowski JM; Wade MR; Tenorio VM; Kuo MS; Brozinick JT; Zhang BB; Birnbaum MJ; Summers SA; Scherer PE
Nat Med; 2011 Jan; 17(1):55-63. PubMed ID: 21186369
[TBL] [Abstract][Full Text] [Related]
56. Inhibition of de novo ceramide synthesis reverses diet-induced insulin resistance and enhances whole-body oxygen consumption.
Ussher JR; Koves TR; Cadete VJ; Zhang L; Jaswal JS; Swyrd SJ; Lopaschuk DG; Proctor SD; Keung W; Muoio DM; Lopaschuk GD
Diabetes; 2010 Oct; 59(10):2453-64. PubMed ID: 20522596
[TBL] [Abstract][Full Text] [Related]
57. Sphingolipids and insulin resistance: the five Ws.
Summers SA
Curr Opin Lipidol; 2010 Apr; 21(2):128-35. PubMed ID: 20216312
[TBL] [Abstract][Full Text] [Related]
58. Link between plasma ceramides, inflammation and insulin resistance: association with serum IL-6 concentration in patients with coronary heart disease.
de Mello VD; Lankinen M; Schwab U; Kolehmainen M; Lehto S; Seppänen-Laakso T; Oresic M; Pulkkinen L; Uusitupa M; Erkkilä AT
Diabetologia; 2009 Dec; 52(12):2612-5. PubMed ID: 19669729
[TBL] [Abstract][Full Text] [Related]
59. Central role of ceramide biosynthesis in body weight regulation, energy metabolism, and the metabolic syndrome.
Yang G; Badeanlou L; Bielawski J; Roberts AJ; Hannun YA; Samad F
Am J Physiol Endocrinol Metab; 2009 Jul; 297(1):E211-24. PubMed ID: 19435851
[TBL] [Abstract][Full Text] [Related]
60. Plasma ceramides are elevated in obese subjects with type 2 diabetes and correlate with the severity of insulin resistance.
Haus JM; Kashyap SR; Kasumov T; Zhang R; Kelly KR; Defronzo RA; Kirwan JP
Diabetes; 2009 Feb; 58(2):337-43. PubMed ID: 19008343
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
